Sanara MedTech enters $75M at-the-market equity offering agreement with Cantor Fitzgerald

Sanara MedTech Inc.

Up to $75M of common stock may be sold from time to time through Cantor Fitzgerald & Co.
Cantor receives a 3.0% commission on gross proceeds from each sale.
Sales are at-the-market offerings under Rule 415(a)(4); no obligation to sell any shares.
Agreement may be suspended or terminated by either party upon notice.
Shares are registered under existing S-3 shelf registration statement (File No. 333-251652).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

Sanara MedTech Inc. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at up to $75,000,000 (effective 2023-02-24).

Action: entry
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Value: up to $75,000,000
Effective: 2023-02-24

Exact text from the filing

On February 24, 2023, Sanara MedTech Inc., a Texas corporation (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which the Company may offer and sell from time to time, to or through Cantor, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $75,000,000 (the “Shares”).

View on SEC.gov

276 material agreements filed in the last 30 days. Browse all material agreements →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.